Research programme: curcumin analogues - Traverse Biosciences
Alternative Names: CMC 2.24; TRB N0224Latest Information Update: 28 Apr 2025
At a glance
- Originator State University of New York at Stony Brook
- Developer The Feinstein Institute for Medical Research; Traverse Biosciences
- Class Small molecules
- Mechanism of Action Inflammation mediator inhibitors; Matrix metalloproteinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroblastoma; Osteoarthritis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Neuroblastoma in USA (PO)
- 28 Apr 2025 No recent reports of development identified for research development in Osteoarthritis in USA (PO)
- 25 Apr 2023 Early research in Osteoarthritis is still ongoing in USA (Traverse Biosciences pipeline, April 2023)